BioCentury | Apr 26, 2019
Clinical News

Maruho planning Japanese submission for pruritus therapy

...atopic dermatitis patients with moderate-to-severe pruritus. Maruho has Japanese rights to the humanized mAb against IL-31...
...Skin Health unit of Nestle S.A. (SIX:NESN). Hongjiang Li, Staff Writer nemolizumab (CIM331) Chugai Pharmaceutical Co. Ltd. Maruho Co. Ltd. Interleukin-31 (IL-31) receptor...
BioCentury | Mar 15, 2019
Clinical News

Galderma planning Phase III program for atopic dermatitis therapy

...corticosteroids. The company plans to start a Phase III program of the humanized mAb against IL-31...
...and Taiwan from Chugai Pharmaceutical Co. Ltd. (Tokyo:4519). Hongjiang Li, Staff Writer nemolizumab (CIM331) Chugai Pharmaceutical Co. Ltd. Nestle S.A. Interleukin-31 (IL-31) receptor...
BioCentury | May 4, 2018
Financial News

Ex-Synageva team planning Kiniksa IPO

...2016, Kiniksa acquired KPL-716 from Biogen Inc. (NASDAQ:BIIB). The therapy is a mAb that inhibits IL-31...
BioCentury | Apr 28, 2018
Financial News

Ex-Synageva team planning Kiniksa IPO

...2016, Kiniksa acquired KPL-716 from Biogen Inc. (NASDAQ:BIIB). The therapy is a mAb that inhibits IL-31...
BioCentury | Aug 1, 2016
Company News

Chugai, Galderma deal

...milestones and royalties. Chugai will remain responsible for manufacturing and supplying the humanized mAb against IL-31...
BioCentury | Mar 14, 2016
Clinical News

Nemolizumab: Phase II data

...Japan Product: Nemolizumab ( CIM331 ) Business: Dermatology Molecular target: Interleukin-31 (IL-31) receptor Description: Humanized mAb targeting IL-31...
BioCentury | Oct 4, 2010
Strategy

Times changed

...25 PDUFA date. ZymoGenetics also has six biologics in preclinical testing, including a mAb against IL-31...
BioCentury | Sep 15, 2008
Company News

ZymoGenetics, Merck KGaA deal

...$77.1 million in the first half. Separately, the partners restructured their 2004 deal to co-develop IL-31...
...to treat inflammatory bowel disease, RA and MS. ZymoGenetics will assume development and commercialization of IL-31...
BioCentury | Feb 5, 2007
Strategy

Sticking to core values

...Similarly, as part of its deal with ZGEN, NVO is looking at the potential of anti-IL-31...
BioCentury | Sep 25, 2006
Strategy

Midcap wake-up call

...alpha for cartilage repair and psoriasis, respectively. The partners also agreed to co-develop and co-commercialize IL-31...
Items per page:
1 - 10 of 19